Oragenics to License Sigyn's CardioDialysis for Brain Injury

Oragenics (NYSE American: OGEN) and Sigyn Therapeutics Inc. (OTCQB: SIGY) have announced the signing of a letter of intent under which Oragenics expects to obtain an exclusive license to develop and commercialize Sigyn’s CardioDialysis™ blood purification technology for traumatic brain injury and chronic neurodegenerative diseases. This potential acquisition complements Oragenics’ Phase IIa intranasal neurosteroid candidate ONP-002, creating a proposed dual-modality approach that targets inflammation on both sides of the blood-brain barrier. The combination of a blood purification technology and an intranasal therapy could offer a comprehensive treatment strategy for conditions like traumatic brain injury (TBI), which currently lacks effective FDA-approved therapies.

Oragenics is a clinical-stage biotechnology company focused on developing brain-targeted therapeutics through its proprietary intranasal delivery technology. Its lead candidate, ONP-002, is being developed as a potential first-in-class treatment for concussion and mild traumatic brain injury, with clinical trials planned in Australia and subsequent U.S. Phase 2b trials. The company’s intranasal platform has potential applications across multiple neurological conditions, including Parkinson’s disease, Alzheimer’s disease, PTSD, and anxiety disorders. By potentially adding CardioDialysis to its pipeline, Oragenics aims to address the inflammatory cascade that occurs after brain injury, which is often a key driver of long-term damage.

Sigyn Therapeutics’ CardioDialysis technology is designed to remove harmful molecules from the blood, such as cytokines and other inflammatory mediators, offering a blood purification approach that could be used in acute and chronic neurological conditions. The partnership highlights a growing trend in biotech to combine therapies targeting different mechanisms of action for complex diseases. As noted in the press release, full details are available at https://ibn.fm/VD4RO, and for ongoing updates on OGEN, investors can visit the company’s newsroom at https://ibn.fm/OGEN.